**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 44645

**Manuscript Type:** META-ANALYSIS

**Adiponectin polymorphisms and the risk of gestational diabetes mellitus: A meta-analysis**

Huang LT *et al*. Adiponectin polymorphisms and GDM

Lin-Ting Huang, Shi-Lan Wu, Xin Liao, Shu-Juan Ma, Hong-Zhuan Tan

**Lin-Ting Huang, Shi-Lan Wu, Xin Liao, Shu-Juan Wu, Hong-Zhuan Tan,** Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410083, Hunan Province, China

**ORCID number:** Lin-Ting Huang (0000-0002-7352-9832); Shi-Lan Wu (0000-0003-0473-1313); Xin Liao (0000-0002-9640-8638); Shu-Juan Ma (0000-0002-7858-067X); Hong-Zhuan Tan (0000-0002-4292-5947).

**Author contributions:** Huang LT study inception, acquisition of data, analysis and interpretation data, drafting the article, final approve; Wu SL acquisition of data, analysis and interpretation data, revision the article, final approve; Xin L acquisition of data, analysis and interpretation data, revision the article, final approve; Ma SJ interpretation data, revision the article, final approve; Tan HZ conception and design of the study, critical revision, final approve.

**Supported by** the National Nature Science Foundation of China, No. 81773535.

**Conflict-of-interest** **statement:** The authors deny any conflict of interest.

**PRISMA Checklist:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA Checklist.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Hong-Zhuan Tan, MD, PhD, Professor,** Xiangya School of Public Health, Central South University, Changsha 410008, Hunan Province, China. [tanhz99@qq.com](file:///F:\Foxmail\Temp\tanhz99@qq.com)

**Telephone:** +86-731-88858435

**Fax:** +86-731-84805454

**Received:** November 20, 2018

**Peer-review started:** November 21, 2018

**First decision:** December 15, 2018

**Revised:** December 24, 2018

**Accepted:** January 3, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Adiponectin (ADIPOQ) is an important factor involved in the regulation of both carbohydrate and lipid metabolism. Polymorphisms in the ADIPOQ gene are known to influence an individual’s predisposition to metabolic syndrome and type 2 diabetes. Moreover, women with gestational diabetes mellitus (GDM) are at an increased risk of developing type 2 diabetes. Several studies have been conducted previously to assess the association between ADIPOQ polymorphisms and GDM; however, the results of the association are inconclusive.

***AIM***

To quantitatively evaluate the association between *ADIPOQ +45T/G*, *+276G/T*, and *-11377C/G* polymorphisms and the risk of GDM.

***METHODS***

A systematic search of EMBASE, PubMed, CNKI, Web of Science, and WANFANG DATA was conducted up to 20 October 2018. We calculated merged odds ratios (ORs) with 95%CIs using fixed-effect models or random-effect models due to the between-study heterogeneity to evaluate the association between *AIDPOQ +45T/G*, *+276G/T*, *-11377C/G* polymorphisms and the risk of GDM. The subgroup analyses were performed by ethnicity. Publication and sensitivity bias analyses were performed to test the robustness of the association. All statistical analyses were conducted using Stata12.0.

***RESULTS***

Nine studies of *+45T/G* included 1024 GDM cases and 1059 controls, 5 studies of *+276G/T* included 590 GDM cases and 595 controls, and 5 studies of *-11377C/G* included 722 GDM cases and 791 controls. Pooled ORs indicated that *+45T/G* increased GDM risk in Asians (allelic model: OR = 1.47, 95%CI: 1.27-1.70, *P* = 0.000; dominant model: OR = 1.54, 95%CI: 1.27-1.85, *P* = 0.000; recessive model: OR=2.00, 95%CI: 1.43-2.85, *P* = 0.000), not in South America (allelic model: OR = 1.21, 95%CI: 0.68-2.41, *P* = 0.510; dominant model: OR = 1.13, 95%CI: 0.59-2.15, *P* = 0.710; recessive model: OR = 2.18, 95%CI: 0.43-11.07, *P* = 0.350). There were no significant associations between *+276G/T* (allelic model: OR = 0.88, 95%CI: 0.74-1.05, *P* = 0.158; dominant model: OR = 0.91, 95%CI: 0.65-1.26, *P* = 0.561; recessive model: OR = 0.82, 95%CI: 0.64-1.05, *P* = 0.118) or *-11377C/G* (allelic model: OR = 0.96, 95%CI: 0.72-1.26, *P* = 0.750; dominant model: OR = 1.00, 95%CI: 0.73-1.37, *P* = 0.980; recessive model: OR = 0.90, 95%CI: 0.61-1.32, *P* = 0.570) and the risk of GDM.

***CONCLUSIONS***

Our meta-analysis shows the critical role of the *ADIPOQ +45T/G* polymorphism in GDM, especially in Asians. Studies focused on delineating ethnicity-specific factors with larger sample sizes are needed.

**Key words:** Gestational diabetes mellitus; Single nucleotide; Polymorphism; Adiponectin; Gene; Meta-analysis

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** No consensus is available in the literature about the association of adiponectin polymorphisms and the risk of gestational diabetes mellitus (GDM). As far as we know, only *+45T/G* was involved in a previous meta-analysis with small sample size and obvious heterogeneity. We evaluate the association between *ADIPOQ +45T/G*, *+276G/T*, and *-11377C/G* polymorphisms and GDM with bigger sample size, less heterogeneity. Moreover, the subgroup analyses were performed by ethnicity.

Huang LT, Wu SL, Liao X, Ma SJ, Tan HZ. Adiponectin polymorphisms and the risk of gestational diabetes mellitus: A meta-analysis. *World J Clin Cases* 2019; In press

**INTRUDUCTION**

Gestational diabetes mellitus (GDM) is a condition of impaired glucose tolerance during pregnancy in women without a previous diagnosis of diabetes. It is associated with serious complications for both mother and child in the pre- and postnatal period[[1](#_ENREF_1)]. Many kinds of risk factors contribute to GDM, such as ethnicity, genetics, family history, dietary habits and physical activity[1]. Obesity is a usual risk factor for GDM and can cause insulin resistance. Many biochemical mediators compounded in the adipose tissue and secreted in the circulatory system, such as resistin, adiponectin and leptin, are suggested to correlate obesity and insulin resistance[[2](#_ENREF_2)].

Adiponectin is produced in adipose tissue and modulates various metabolic processes, including lipid metabolism, glucose and fatty acid oxidation. This hormone decreases insulin resistance, improves lipid metabolism and exerts anti-inflammatory properties. Decreased plasma adiponectin levels were observed in patients with type 2 diabetes, metabolic syndrome and obesity[[3](#_ENREF_3)]. During normal pregnancy, adiponectin levels progressively decline, with its plasma concentration reaching even lower in GDM women[[1](#_ENREF_1)]. Previous studies suggested that adiponectin single nucleotide polymorphisms (SNPs) could influence the concentration of plasma adiponectin and subsequently insulin sensitivity[[4-6](#_ENREF_4)].

Studies have paid attention to the SNPs *+45T/G* in exon 2and *+276G/C in* intron 2, *-11391G/A* and *-11377C/G* in the promoter region. The two adiponectin linkage disequilibrium blocks are where these four variants located within. Block 1, comprising the promoter sequence spanning the region -14811 to -4120, and block 2, encompassing the exons in the region -450 to +4545[[2](#_ENREF_2)]. The conclusions of these studies have been disputed regarding whether the metabolic phenotypes of GDM are influenced by the variability at this locus and which polymorphisms contribute to this effect. For example, Low *et al*[[7](#_ENREF_7)] reported that a significant association was found between *SNP 45T/G* and GDM, and normal patients with the TT genotype had significantly higher plasma adiponectin levels compared to those in the TG or GG genotype group. Beltcheva *et al*[[1](#_ENREF_1)] reported that *-11377C/G* is associated with gestational diabetes. According to Daher *et al*[[8](#_ENREF_8)], GDM is not associated with +45T/G and -11377C/G polymorphisms. Reasons for the conflicting results are small samples in a single study and the hereditary difference of ethnicity.

As the results are discrepant and +45T/G was the only polymorphism which participated in the meta-analysis, our study is meant to evaluate whether and to what extent adiponectin polymorphisms contribute to GDM.

**MATERIALS AND METHODS**

***Literature search strategy***

Electronic databases PubMed, EMBASE, Web of Science, WANFANG DATA, and CNKI were used to search possibly correlation articles on human genetic studies of ADIPOQ and GDM that had been published up to 20 October 2018. The search terms used were: “Gestational diabetes mellitus” or “GDM” and “adiponectin” or “ADIPOQ” and “single nucleotide polymorphism” or “polymorphism”.

***Selection criteria and data extraction***

We searched the database and identified eighty-seven articles. The selection criteria of the publications as follow: (A) well-designed case control studies on genetic correlation of ADIPOQ and the risk of GDM; (B) clear diagnostic criteria for GDM; (C) independent and sufficient genotype data must be contained in the original papers and the data can calculate ORs and 95% confidence intervals (CI); (D) there should be at least two articles that have studied each polymorphism that we used in our meta-analysis. During the selection, we removed 25 articles for duplicate publication and excluded 49 articles for review, such as animal studies, case reports with unrelated outcomes or other diseases and articles with no *ADIPOQ +45T/G* or *+276G/T* or *-11377C/G* reported.

Finally, thirteen articles were adopted in this meta-analysis. Among them, 9 studies investigated *+45T/G*, 5 studies investigated *+276G/T* and 5 studies investigated *-11377C/G*. A flow diagram of study selection is presented in Figure 1.

Data were extracted by two researchers independently. We have extracted the following information from every included study: first author, years of publication, country, ethnicity, matching criteria, genotyping method, numbers of cases and controls, minor allele frequency in controls and Hardy-Weinberg equilibrium (HWE) status. We obtained the HWE status of controls by calculating from genotype distributions using STATA12.0. Newcastle-Ottawa quality assessment scale (NOS) was used for quality assessment of primary studies. The study will be regarded as a high-quality study when it has a NOS scores ≥ 6 (Table 1)[[9](#_ENREF_9)].

***Statistical analysis***

We used Stata12.0 software for statistical analysis. a fixed-effect model or random-effect model was used to merge OR and 95%CI base on allelic models, recessive models and dominant models to evaluate the association between each genetic variant and the risk of GDM. The *Z*-test was used for determining the significance of the merged OR. *P* < 0.05 was considered statistically significant.

We used the Cochran *Q* test to assess the heterogeneity among the studies and Higgins *I²* statistic for quantifying the heterogeneity. We used the random-effect model as merging method when the variant association present significant interstudy heterogeneity (*Q* test, *P*-value < 0.05, or *I²* > 50%), otherwise, we used the fixed-effect model. Subgroup analyses were performed based on the ethnicity of the study population to evaluate ethnic-specific effect. Publication bias was tested by Begg’s funnel plot.

The statistical methods of this study were reviewed by Shi-Min Hu from Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University.

**RESULTS**

***Main characteristics of all the included studies***

Thirteen studies were adopted in this meta-analysis; among them, nine studies were about the association of *+45T/G* and GDM[[2](#_ENREF_2),[4](#_ENREF_4),[7](#_ENREF_7),[8](#_ENREF_8),[10-14](#_ENREF_10)], five studies were about the association of *+276G/T* and GDM[[4](#_ENREF_4),[10](#_ENREF_10),[12-14](#_ENREF_12)], and five studies were about the association of *-11377C/G* and GDM[[1](#_ENREF_1),[3](#_ENREF_3),[8](#_ENREF_8),[15](#_ENREF_15),[16](#_ENREF_16)]. In total, 1667 GDM cases and 1682 controls were included; ten studies were from Asian descendants[[2](#_ENREF_2),[4](#_ENREF_4),[7](#_ENREF_7),[10-15](#_ENREF_10)], two studies were from European descendants[[1](#_ENREF_1),[3](#_ENREF_3)], and one study was from a South American descendant[[8](#_ENREF_8)]. Detailed characteristics of all studies included are shown in Table 2.

***Association between +45T/G and GDM***

Nine articles evaluated the association of *+45T/G* and GDM; eight of them were conducted in Asia and 1 in South America, with a total of 1024 GDM cases and 1059 controls. Heterogeneity test *P* > 0.05, *I*² < 50%; the fixed-effect model was used.

The pooled results suggested a significant association between *+45T/G* and GDM (allelic model: OR = 1.45, 95%CI: 1.26-1.67; dominant model: OR = 1.50, 95%CI: 1.25-1.79; recessive model: OR = 2.00, 95%CI: 1.42-2.84). Ethnicity-based subgroup analysis showed that *+45T/G* was associated with GDM in Asians (allelic model: OR = 1.47, 95%CI: 1.27-1.70; dominant model: OR = 1.54, 95%CI: 1.27-1.85; recessive model: OR = 2.00, 95%CI: 1.43-2.85). However, there was no association of *+45T/G* with the risk of GDM in South America (allelic model: OR = 1.21, 95%CI: 0.68-2.41; dominant model: OR = 1.13, 95%CI: 0.59-2.15; recessive model: OR=2.18, 95%CI: 0.43-11.07)(Figure 2, Table 3).

***Association between +276G/T and GDM***

The association between *+276G/T* and the risk of GDM was investigated by five studies, including 590 GDM cases and 595 controls. Heterogeneity test *P* > 0.05, *I*² < 50%, the fixed-effect model was used.

The results showed that *+276G/T* was not associated with the risk of GDM (allelic model: OR = 0.88, 95%CI: 0.74-1.05; dominant model: OR = 0.91, 95%CI: 0.65-1.26; recessive model: OR = 0.82, 95%CI: 0.64-1.05)(Figure 3, Table 3).

***Association between -11377C/G and GDM***

The association between *-11377C/G* and the risk of GDM was investigated by five studies, of which 2 were conducted in Asia, 2 were conducted in Europe, and 1 was conducted in South America, with a total of 722 GDM cases and 791 controls. Heterogeneity test *P* < 0.05, *I*² > 50%; the random-effect model was used.

The results showed that *-11377C/G* was not associated with the risk of GDM (allelic model: OR = 0.96, 95%CI: 0.72-1.26; dominant model: OR = 1.00, 95%CI: 0.73-1.37; recessive model: OR = 0.90, 95%CI: 0.61-1.32). Ethnicity-based subgroup analysis also showed that *-11377C/G* was not associated with GDM in Asian (allelic model: OR = 1.04, 95%CI: 0.77-1.41; dominant model: OR = 1.09, 95%CI: 0.79-1.50; recessive model: OR = 0.97, 95%CI: 0.51-1.86), European (allelic model: OR = 0.94, 95%CI: 0.45-1.96; dominant model: OR = 1.00, 95%CI: 0.42-2.33; recessive model: OR = 0.87, 95%CI: 0.51-1.49) and South American populations (allelic model: OR = 0.80, 95%CI: 0.50-1.29; dominant model: OR = 0.77, 95%CI: 0.44-1.36; recessive model: OR = 0.81, 95%CI: 0.51-1.86)(Figure 4, Table 3).

***Publication bias***

We used the Egger regression asymmetry test and Begg’s funnel plot to assess the public bias of the studies. The evidence of publication bias cannot be found in the meta-analysis of +45T/G (allelic model: continuity corrected *P*-value = 1.000, Egger regression asymmetry test *t* = -0.62, *P* = 0.554; recessive model: continuity corrected *P*-value = 0.466, Egger regression asymmetry test *t* = -0.15, *P* = 0.883), *+276G/T* (allelic model: continuity corrected *P*-value = 0.26, Egger regression asymmetry test *t* = -1.24, *P* = 0.282) and *-11377C/G* (allelic model: continuity corrected *P*-value = 0.221, Egger regression asymmetry test *t* = -2.48, *P* = 0.089)(Figure 5).

***Sensitivity analysis***

To assess the stability of the results, we performed the sensitivity analysis by sequentially excluding individual studies for each meta-analysis. For the association between *+45T/G*, *+276G/T*, *-11377C/G* and GDM, There was no significant change of corresponding merged ORs when one study was sequentially excluded from every meta-analysis. Therefore, the results of our meta-analysis are stable and reliable (Figure 6).

**DISCUSSION**

Adiponectin has been considered an important factor in regulating glucose and lipid metabolism. It is secreted by adipose tissue, which has a negative correlation with insulin resistance to type 2 diabetes and metabolic syndrome. ADIPOQ can increase insulin sensitivity, anti-inflammation, and anti-atherosclerosis, promote glucose uptake in muscle tissue and inhibit intrahepatic synthetic glucose[[17](#_ENREF_17)].

In the chromosomal region where the adiponectin gene is located, there are susceptible sites of T2D and metabolic syndrome, and its SNPs can affect the level of adiponectin in blood, leading to obesity insulin resistance and the occurrence of T2D[[15](#_ENREF_15)].

Plasma adiponectin levels gradually decreased with gestational week during pregnancy, consistent with the gradual decrease of insulin sensitivity[[3](#_ENREF_3)], and plasma adiponectin levels decreased more significantly in GDM women. This phenomenon is closely related to the decreased transcriptional activity of ADIPOQ during pregnancy. Previous studies revealed the association of ADIPOQ SNPs, such as *+45T/G*[[1](#_ENREF_1),[2](#_ENREF_2),[4](#_ENREF_4),[7](#_ENREF_7),[8](#_ENREF_8),[10-14](#_ENREF_10)], *+276G/T*[[1](#_ENREF_1),[4](#_ENREF_4),[10](#_ENREF_10),[12](#_ENREF_12),[13](#_ENREF_13),[18](#_ENREF_18)], *-11377C/G*[[1](#_ENREF_1),[3](#_ENREF_3),[8](#_ENREF_8),[15](#_ENREF_15),[16](#_ENREF_16)], *-3971A/G*[[13](#_ENREF_13),[19](#_ENREF_19)] and *-11426A/G*[[15](#_ENREF_15),[19](#_ENREF_19)], and the risk of GDM. A total of 66.7% (6 of 9) of the studies adopted in this meta-analysis reported that the *+45T/G* polymorphism increased the risk of GDM, and 40% (2 of 5) reported that the *-11377C/G* polymorphism was associated with GDM. A higher prevalence of the G allele was observed among women with GDM. All studies regarding *+276G/T* reported that this polymorphism had no association with the risk of GDM.

Thirteen studies were included in our study; nine studies were about *+45T/G*, with 1024 cases and 1059 controls, five studies were about *+276G/T*, with 590 cases and 595 controls, and five studies were about *-11377C/G*, with 722 cases and 791 controls. We not only had a larger sample size than previous studies but also performed subgroup analyses based on the ethnicity of the study population to evaluate ethnic-specific effects. +45T/G was proved by our meta-analysis that it is a risk factor for GDM (allelic model: OR = 1.45, 95%CI: 1.26-1.67, *P* = 0.000), and 66.7% (six of nine) of studies reported a positive result[[2](#_ENREF_2),[4](#_ENREF_4),[7](#_ENREF_7),[10](#_ENREF_10),[12](#_ENREF_12),[14](#_ENREF_14)]. Subgroup analysis showed that *+45T/G* was associated with GDM in Asians (allelic model: OR = 1.47, 95%CI: 1.27-1.70, *P* = 0.000) but not in South Americans. In addition, no association of *+276G/T* and *-11377C/G* and the risk of GDM were observed.

Obvious heterogeneity was detected among the *-11377C/G* studies (allelic model: *I²* = 64.0%, *P* = 0.03, dominant model: *I²* = 55.0%, *P* = 0.06, recessive model: *I²* = 32.0%, *P* = 0.21). We used subgroup analysis based on ethnicity, and the heterogeneity could not be reduced, indicating that a small sample size and other reasons may have influenced the heterogeneity. The association of *-11377C/G* with the risk of GDM remain to be verified by further studies. No heterogeneity was found in the studies of *+45T/G* (allelic model: *I²* = 14.3%, *P* = 0.32, dominant model: *I²* = 18.1%, *P* = 0.28, recessive model: *I²* = 0.0%, *P* = 0.90) and *+276G/T* (allelic model: *I²* = 0.0%, *P* = 0.74, dominant model: *I²* = 0.0%, *P* = 0.78, recessive model: *I²* = 0.0%, *P* = 0.83), so the conclusion that *+45T/G* has, but *+276G/T* has no association with the risk of GDM is relatively reliable. Begg’s funnel plot was used to test publication bias. The test shows that there is no publication bias among the studies. Sensitivity analysis indicated that the results are stable and reliable.

SNP *+45T/G* is a synonymous mutation (GGT→GGG, Gly15Gly) at exon 2. The results of Yang *et al*[[20](#_ENREF_20)] indicated that *+45T/G* polymorphism may influence the expression of adiponectin by influencing RNA splicing and stability. Some studies reported that the G allele of *+45T/G* polymorphism in the adiponectin gene is associated with obesity, insulin resistance and T2D in several population. Very few studies have investigated the association of adiponectin *+45T/G* polymorphism with GDM and the results of these studies were controversial.

As far as we know, only *+45T/G* was involved in a previous meta-analysis that reported no association of adiponectin *+45T/G* polymorphism with the risk of GDM (allelic model: OR = 1.17, 95%CI: 0.79-1.76; dominant model: OR = 0.86, 95%CI: 0.50-1.48; recessive model: OR = 1.21, 95%CI: 0.62-2.33)[[21](#_ENREF_21)]. The reason for this controversy is most likely the following: (1) the small sample size (case = 875, control = 884); (2) obvious heterogeneity (all *P*-values for heterogeneity less than 0.01); and (3) false HWE status of 25% studies (2 of 8) involved in that meta-analysis will cause insufficient power which may lead to the false-negative results.

The role of *+276G/T* in the pathogenesis of metabolic syndrome and diabetes mellitus has also been reported to be contradictory. Commonly, the T allele has association with higher adiponectin level and protection against T2D[[22](#_ENREF_22), [23](#_ENREF_23)], some studies showed that T carriers have higher risk of obesity and diabetes[[24](#_ENREF_24), [25](#_ENREF_25)], or +276G/T polymorphism is not associated with T2D and GDM[[26](#_ENREF_26)].

All the literatures on *+276G/T* polymorphism included in our study come from the Chinese population. This result suggests that *+276G/T* in the Chinese population may associate with the risk of GDM. The studies about the association between *+276G/T* and GDM from other countries could not be found. Geographical, environmental and genetic factors of different ethnic groups lead to different susceptibility to diabetes; therefore we need more studies about the association between *+276G/T* and GDM of other ethnic groups to reach reliable conclusions.

Zhang *et al*[[27](#_ENREF_27)] found that adiponectin gene promoter region has four transcription stimulatory protein (SP1) binding sites, while the G allele of *- 11377 C/G* in the promoter region of the peptide loci can change one of the DNA sequence of SP1 binding sites, leading to the SP1 loci lose binding force, which may reduce the adiponectin gene transcription activity, inhibit the expression of genes, led to lower plasma adiponectin, which could associate with glucolipid metabolic abnormalities and insulin resistance. Consistent with the results of Vasseur *et al*[[28](#_ENREF_28)], Petrone *et al*[[29](#_ENREF_29)] reported that *-11377G* haplotype is associated with low plasma adiponectin levels and T2D. However, due to ethnic and geographical differences, the results of studies on the association between adiponectin gene *-11377C/G* polymorphism and diabetes mellitus are not completely consistent[[30](#_ENREF_30)].

According to the literatures on *-11377C/G* polymorphism included in our studies, Asians accounted for 40%, Europeans for 40%, and South Americans for 20%. Due to the small sample size and large heterogeneity of each ethnic subgroup, our results which are inconsistent with the previous studies are unreliable.

The limitation of this study should be considered. First, the number of cases and controls involved in the meta-analysis for exploring the association of ADIPOQ and GDM in different ethnicities may have little power, and studies with larger sample sizes and multiple ethnicities are needed. Second, GDM has complicated cases, with genetic susceptibility, environmental triggers and acquired dispositions such as age, gestational weeks, condition of nutrition, and physique. In this meta-analysis, we failed to conduct a multivariate analysis of confounders. Therefore, further comprehensive studies with strict matching criteria for cases and controls are needed. Third, few studies have reported the association between polymorphisms and serum adiponectin levels, so genotype-phenotype analysis was prevented[[21](#_ENREF_21)].

In conclusion, our meta-analysis reveals the association of the *ADIPOQ +45T/G* polymorphism and the risk of GDM; this polymorphism increases GDM risk in Asian populations. Another two polymorphisms, *+276G/T* and *-11377C/G*, seem to have no association with the risk of GDM. Prospective studies of high quality with larger sample sizes are required to reveal the association of ADIPOQ polymorphisms with GDM, the existence of ethnicity-specific factors, and the role ADIPOQ polymorphisms play in pathology.

**Article Highlights**

***Research background***

Many biochemical mediators that are synthesized in adipose tissue and secreted in the circulation, such as leptin, adiponectin (ADIPOQ) and resisting are thought to be involved in obesity and insulin resistance. ADIPOQ is produced in adipose tissue and regulates a variety of metabolic processes such as lipid metabolism, glucose and fatty acid oxidation. This hormone can reduce insulin resistance, improve lipid metabolism, and exert anti-inflammatory effects. Plasma ADIPOQ levels are decreased in patients with type 2 diabetes, metabolic syndrome, and obesity. Previous studies have shown that ADIPOQ single nucleotide polymorphisms can affect plasma ADIPOQ concentrations, which in turn affect insulin sensitivity.

***Research motivation***

Previous studies have evaluated the relationship between ADIPOQ polymorphisms and gestational diabetes mellitus (GDM), but the results of the association between ADIPOQ polymorphisms and GDM are uncertain.

***Research objectives***

We evaluate the association between *ADIPOQ +45T/G*, *+276G/T*, and *-11377C/G* polymorphisms and GDM with bigger sample size, less heterogeneity. Moreover, the subgroup analyses were performed by ethnicity.

***Research methods***

Potentially related articles on human fat metabolism and GDM gene research published before 20 October 2018 were retrieved through the electronic databases EMBASE, Web of Science, PubMed, WANFANG DATA and China National Knowledge Infrastructure. Fixed-effect models or random-effect models were used to calculated Pooled odds ratios (ORs) with 95% confidence intervals (CIs), based on the between-study heterogeneity to evaluate the association between *AIDPOQ +45T/G*, *+276G/T*, *-11377C/G* polymorphisms and the risk of GDM.

***Research results***

Nine *+45T/G* studies included 1024 GDM cases and 1059 controls, 5 *+276G/T* studies included 590 GDM cases and 595 controls, and 5 *-11377C/G* studies included 722 GDM cases and 791 controls. Pooled ORs showed *+45T/G* increased Asian GDM risk (allele model OR = 1.47, 95%CI: 1.27-1.70, *P* = 0.000; dominant model OR = 1.54, 95%CI: 1.27-1.85, *P* = 0.000; recessive mode: OR = 2.00, 95%CI: 1.43-2.85, *P* = 0.000), non-South American (equal pattern: OR = 1.21, 95%CI: 0.68-2.41, *P* = 0.510; dominant model OR = 1.13, 95%CI: 0.59-2.15, *P* = 0.710; recessive mode OR = 2.18, 95%CI: 0.43-11.07, *P* = 0.350). There was no significant correlation between *+276G/T* (allele model OR = 0.88, 95%CI: 0.74-1.05, *P* = 0.158; dominant model OR = 0.91, 95%CI: 0.65-1.26, *P* = 0.561; recessive mode: OR = 0.82, 95%CI: 0.64-1.05, *P* = 0.118) or *-11377C/G* (equal pattern: OR = 0.96, 95%CI: 0.72-1.26, *P* = 0.750; dominant model OR = 1.00, 95%CI: 0.73-1.37, *P* = 0.980; recessive model: OR = 0.90, 95%CI: 0.61-1.32, *P* = 0.570) and GDM risk.

***Research conclusions***

Our meta-analysis reveals the association of the *ADIPOQ +45T/G* polymorphism and the risk of GDM; this polymorphism increases GDM risk in Asian populations.

***Research perspectives***

In order to reveal the association of ADIPOQ polymorphisms with GDM, the existence of ethnicity-specific factors, and the role ADIPOQ polymorphisms play in pathology, Studies focused on delineating ethnicity-specific factors with larger sample sizes are needed.

**REFERENCES**

1 **Beltcheva O**, Boyadzhieva M, Angelova O, Mitev V, Kaneva R, Atanasova I. The rs266729 single-nucleotide polymorphism in the adiponectin gene shows association with gestational diabetes. *Arch Gynecol Obstet* 2014; **289**: 743-748 [PMID: 24068295 DOI: 10.1007/s00404-013-3029-z]

2 **Takhshid MA**, Haem Z, Aboualizadeh F. The association of circulating adiponectin and + 45 T/G polymorphism of adiponectin gene with gestational diabetes mellitus in Iranian population. *J Diabetes Metab Disord* 2015; **14**: 30 [PMID: 25909078 DOI: 10.1186/s40200-015-0156-z]

3 **Pawlik A**, Teler J, Maciejewska A, Sawczuk M, Safranow K, Dziedziejko V. Adiponectin and leptin gene polymorphisms in women with gestational diabetes mellitus. *J Assist Reprod Genet* 2017; **34**: 511-516 [PMID: 28050671 DOI: 10.1007/s10815-016-0866-2]

4 **Han Y**, Zheng YL, Liu MH, Fan YP. Association of adiponectin gene single nucleotide polymorphism with gestational diabetes mellitus and pregnancy outcomes. *Shiyong Fuchanke Zazhi* 2012; **22**: 743-746

5 **Hara K**, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes* 2002; **51**: 536-540 [PMID: 11812766 DOI: 10.2337/diabetes.51.2.536]

6 **Menzaghi C**, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, Trischitta V, Doria A. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. *Diabetes* 2002; **51**: 2306-2312 [PMID: 12086965 DOI: 10.2337/diabetes.51.7.2306]

7 **Low CF**, Mohd Tohit ER, Chong PP, Idris F. Adiponectin SNP45TG is associated with gestational diabetes mellitus. *Arch Gynecol Obstet* 2011; **283**: 1255-1260 [PMID: 20552210 DOI: 10.1007/s00404-010-1548-4]

8 **Daher S,** Torloni MR, Gueuvoghlanian-Silva BY, Moron AF, Mattar R. Inflammatory mediator gene polymorphisms and gestational diabetes: A review of the literature. *J Reprod Immunol* 2011; **90**: 111-116 [PMID: 21684013 DOI: 10.1016/j.jri.2011.04.008]

9 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]

10 **Gao Y,** Wang W, Wang SS. Association of Adiponectin Gene Single Nucleotide Polymorphism with Gestational Diabetes Mellitus. *Jilin Yixue* 2016; **6**: 1301-1302

11 **Li GH**, Kong LJ, Zhang L, Zhang WY. [Association of adiponectin gene polymorphisms +45T/G with gestational diabetes mellitus and neonate birth weight]. *Zhonghua Yixue Zazhi* 2013; **93**: 3770-3772 [PMID: 24548395]

12 **Li JY,** Ma S, Zhao J, Duan LJ, Sun HY. The correlation between single nucleotide polymorphism of adiponectin gene and gestational diabetes and its effect on pregnancy outcome. *Zhongguo Fuyoubaojian Zazhi* 2017; **22**: 5674-5677

13 **Luan YY,** Guo XH, Yang JH. Study on the correlation between the damage of adiponectin gene polymorphism with gestational impaired glucose. *Zhongguo Shiyanzhenduanxue Zazhi* 2015; 19: 1093-1096

14 **Zhang C,** Liang XX. The relationship between adiponectin gene polymorphism of Guangxi Zhuang ethnic group and gestational diabetes. *Zhongguo Yishi Zazhi* 2014; **9**: 1221-1223 [DOI: 10.3760/cma.j.issn.1008-1372.2014.09.018]

15 **Chen ZY,** Du J. Relationship between diponectin gene polymorphism and gestational diabetes mellitus. *Xiandai Fuchanke Jinzhan* 2011; 20: 718-721

16 **Wang XX,** Zhang L, Zhou GF, Pu XM. Study of the correlation between adiponectin gene polymorphism and gestational diabetes mellitus. *Zhongguo Fuyoubaojian Zazhi* 2016; **31**: 2546-2549

17 **Peng JJ,** Shi FX, Wang HY, Wang ZP, Yuan P. Correlation between adiponectin and gestaional diabetes mellitus. *Zhongguo Fuyoubaojian Zazhi* 2012; **27**: 1314-1316

18 **Zhang J**, Chi H, Xiao H, Tian X, Wang Y, Yun X, Xu Y. Interleukin 6 (IL-6) and Tumor Necrosis Factor α (TNF-α) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in Gestational Diabetes Mellitus in Inner Mongolia. *Med Sci Monit* 2017; **23**: 4149-4157 [PMID: 28846666 DOI: 10.12659/MSM.903565]

19 **Chen XX,** Wei BR, Zhang LF, Yang YM. Association of -3771A/G Polymorphism in Promoter Region of Adiponectin Gene with Gestational Diabetes Mellitus. *Nanchangdaxue Xuebao Yixueban* 2013; **53**: 18-21

20 **Yang WS**, Tsou PL, Lee WJ, Tseng DL, Chen CL, Peng CC, Lee KC, Chen MJ, Huang CJ, Tai TY, Chuang LM. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. *J Mol Med (Berl)* 2003; **81**: 428-434 [PMID: 12750819 DOI: 10.1007/s00109-002-0409-4]

21 **Xu F**, Zhang H, Qi H. No association of adiponectin +45 T/G polymorphism with the risk of gestational diabetes mellitus: Evidence from a meta-analysis. *J Renin Angiotensin Aldosterone Syst* 2016; **17**: 1470320316653283 [PMID: 27296394 DOI: 10.1177/1470320316653283]

22 **Liang Z**, Dong M, Cheng Q, Chen D. Gestational diabetes mellitus screening based on the gene chip technique. *Diabetes Res Clin Pract* 2010; **89**: 167-173 [PMID: 20554072 DOI: 10.1016/j.diabres.2010.04.001]

23 **Pollin TI**, Tanner K, O'connell JR, Ott SH, Damcott CM, Shuldiner AR, McLenithan JC, Mitchell BD. Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene. *Diabetes* 2005; **54**: 268-274 [PMID: 15616038 DOI: 10.2337/diabetes.54.1.268]

24 **Beebe-Dimmer JL**, Zuhlke KA, Ray AM, Lange EM, Cooney KA. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. *Prostate Cancer Prostatic Dis* 2010; **13**: 362-368 [PMID: 20697428 DOI: 10.1038/pcan.2010.27]

25 **Bouatia-Naji N**, Meyre D, Lobbens S, Séron K, Fumeron F, Balkau B, Heude B, Jouret B, Scherer PE, Dina C, Weill J, Froguel P. ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity. *Diabetes* 2006; **55**: 545-550 [PMID: 16443793 DOI: 10.2337/diabetes.55.02.06.db05-0971]

26 **Urbanek M**, Hayes MG, Lee H, Freathy RM, Lowe LP, Ackerman C, Jafari N, Dyer AR, Cox NJ, Dunger DB, Hattersley AT, Metzger BE, Lowe WL Jr. The role of inflammatory pathway genetic variation on maternal metabolic phenotypes during pregnancy. *PLoS One* 2012; **7**: e32958 [PMID: 22479352 DOI: 10.1371/journal.pone.0032958]

27 **Zhang D**, Ma J, Brismar K, Efendic S, Gu HF. A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study. *J Diabetes Complications* 2009; **23**: 265-272 [PMID: 18599322 DOI: 10.1016/j.jdiacomp.2008.05.004]

28 **Vasseur F**, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Leprêtre F, Dupont S, Hara K, Clément K, Bihain B, Kadowaki T, Froguel P. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. *Hum Mol Genet* 2002; **11**: 2607-2614 [PMID: 12354786 DOI: 10.1093/hmg/11.21.2607]

29 **Petrone A**, Zavarella S, Caiazzo A, Leto G, Spoletini M, Potenziani S, Osborn J, Vania A, Buzzetti R. The promoter region of the adiponectin gene is a determinant in modulating insulin sensitivity in childhood obesity. *Obesity (Silver Spring)* 2006; **14**: 1498-1504 [PMID: 17030959 DOI: 10.1038/oby.2006.172]

30 **Enns JE**, Taylor CG, Zahradka P. Variations in Adipokine Genes AdipoQ, Lep, and LepR are Associated with Risk for Obesity-Related Metabolic Disease: The Modulatory Role of Gene-Nutrient Interactions. *J Obes* 2011; **2011**: 168659 [PMID: 21773001 DOI: 10.1155/2011/168659]

**P-Reviewer:** Pastromas S, Cengiz M **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

Duplicates removed (*n* = 25)

Records identified through databases screening (*n* = 87)

Records excluded by screened title and/or abstract, due to review, animal studies, cases report and/or unrelated outcomes or other diseases

(*n* = 47)

Records screened

(*n* = 62)

Full-text articles assessed for eligibility

(*n* = 15)

Records excluded due to No +45T/G,+276G/T or-11377C/G polymorphism

(*n* = 2)

Articles included in quantitative synthesis

(*n* = 13)


9 articles investigated the association between +45T/G and GDM

5 articles investigated the association between


-11377C/G and GDM

5 articles investigated the association between +276G/T and GDM


**Figure 1 Flow diagram of studies selection.**




**Figure 2 Forest plot for the association of *ADIPOQ +45T/G* polymorphism and gestational diabetes mellitus under the allelic model.**




**Figure 3 Forest plot for the association of *ADIPOQ +276G/T* polymorphism and gestational diabetes mellitus under the allelic model.**



**Figure 4** **Forest plot for the association of *ADIPOQ -11377C/G* polymorphism and gestational diabetes mellitus under the allelic model.**



**Figure 5** **Begg’s funnel plots for testing publication bias.** A: *+45T/G* under allelic model; B: *+45T/G* under recessive model; C: *+276G/T* under allelic model; D: *-11377C/G* under allelic model. OR: Odds ratio.



**Figure 6 Sensitivity analyses between ADPIOQ polymorphisms and gestational diabetes mellitus in all studies.** A: *+45T/G* under allelic model; B: *+45T/G* under recessive model; C: *+276G/T* under allelic model; D: *-11377C/G* under allelic model. CI: Confidence interval.

**Table 1 Newcastle-Ottawa quality assessment scale of case control studies**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Year** | **Selection** | | | | **Comparability** | | **Exposure** | | | **Score** |
| **Case definition** | **Case representativeness** | **Control selection** | **Control definition** | **Important confounders** | **Every confounders** | **Ascertainment** | **Consistency** | **Non-response rate** |
| Low *et al*[7] | 2011 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Takhshid *et al*[2] | 2015 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Daher *et al*[8] | 2011 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Han *et al*[4] | 2012 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Gao *et al*[10] | 2016 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Luan *et al*[13] | 2015 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Li *et al*[12] | 2017 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Li *et al*[11] | 2013 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Zhang *et al*[14] | 2014 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Beltcheva *et al*[1] | 2014 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Pawlik *et al*[3] | 2017 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Chen *et al*[15] | 2011 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Wang *et al*[16] | 2016 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |

The quality evaluation content mainly includes three aspects: case selection, baseline comparability and exposure factors with 9 evaluation items. If the evaluation item is met, 1 point is obtained, otherwise 0, and the score ranges from 0 to 9.

**Table 2** **Detailed characteristics of all eligible studies for the association with ADIPOQ single nucleotide polymorphism and gestational diabetes mellitus**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **SNPs** | **Author** | **Year** | **Country** | **Ethnicity** | **Matching criteria** | **Method** | **Sample size** | | **Genotype1** | | **HWE** |
| **case** | **control** | **case** | **control** |
| +45T/G | Low *et al*[7] | 2011 | Malaysia | Asian | NR | Taq PCR | 26 | 53 | 11/13/2 | 35/17/1 | 0.51 |
|  | Takhshid *et al*[2] | 2015 | Iran | Asian | Age | PCR-RELF | 65 | 70 | 37/28/0 | 54/16/0 | 0.28 |
|  | Daher *et al*[8] | 2011 | Brazil | SA | Race | PCR-RELF | 79 | 169 | 61/15/3 | 134/32/3 | 0.51 |
|  | Han *et al*[4] | 2012 | China | Asian | NR | PCR-RELF | 152 | 120 | 63/71/18 | 64/50/6 | 0.34 |
|  | Gao *et al*[10] | 2016 | China | Asian | Age, GW | PCR-RELF | 150 | 150 | 59/66/25 | 81/57/12 | 0.66 |
|  | Luan *et al*[13] | 2015 | China | Asian | Age, GW | NR | 60 | 60 | 33/21/6 | 29/26/5 | 0.81 |
|  | Li *et al*[12] | 2017 | China | Asian | Age, GW | PCR-RELF | 130 | 130 | 53/63/14 | 63/60/7 | 0.13 |
|  | Li *et al*[11] | 2013 | China | Asian | NR | Sequencing | 264 | 172 | 134/113/17 | 97/66/9 | 0.6 |
|  | Zhang *et al*[14] | 2014 | China | Asian | Age, BMI, GW | PCR-RELF | 98 | 135 | 38/43/17 | 73/51/11 | 0.62 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| +276G/T | Han *et al*[4] | 2012 | China | Asian | NR | PCR-RELF | 152 | 120 | 12/66/74 | 11/53/56 | 0.34 |
|  | Gao *et al*[10] | 2016 | China | Asian | Age, GW | PCR-RELF | 150 | 150 | 15/69/66 | 15/60/75 | 0.66 |
|  | Luan *et al*[13] | 2015 | China | Asian | Age, GW | NR | 60 | 60 | 7/26/27 | 3/25/32 | 0.81 |
|  | Li *et al*[12] | 2017 | China | Asian | Age, GW | PCR-RELF | 130 | 130 | 64/58/8 | 60/56/14 | 0.13 |
|  | Zhang *et al*[14] | 2014 | China | Asian | Age, BMI, GW | PCR-RELF | 98 | 135 | 10/45/43 | 13/54/68 | 0.62 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| -11377C/G | Beltcheva *et al*[1] | 2014 | Bulgaria | European | Age, BMI | TaqMan | 130 | 130 | 80/44/6 | 66/50/14 | 0.34 |
|  | Pawlik *et al*[3] | 2017 | Poland | European | NR | TaqMan | 204 | 207 | 92/91/21 | 115/75/17 | 0.34 |
|  | Daher *et al*[8] | 2011 | Brazil | SA | race | PCR-RELF | 79 | 169 | 54/20/5 | 105/50/13 | 0.05 |
|  | Chen *et al*[15] | 2011 | China | Asian | NR | PCR-RELF | 103 | 97 | 55/43/5 | 50/38/9 | 0.65 |
|  | Wang *et al*[16] | 2016 | China | Asian | NR | PCR-RELF | 206 | 189 | 107/84/15 | 106/73/10 | 0.57 |

1Genotype presented as wild type/heterozygous/homozygous. ADIPOQ: Adiponectin; GDM: Gestational diabetes mellitus; SNPs: Single nucleotide polymorphisms; SA: South American; GW: Gestational week; PCR-RELF: Polymerase chain reaction-restriction fragment length polymorphism; BMI: Body mass index; HWE: Newcastle-Ottawa quality assessment scale; NR: Not reported.

**Table 3 Main results of the pooled odds ratios in meta-analysis for the association between ADIPOQ polymorphisms and gestational diabetes mellitus**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **SNPs** | **N** | **Sample size** | | **Allelic model** | | **Dominant model** | | **Recessive model** | |
|  |  | **case** | **control** | **OR (95%CI)** | ***P*** | **OR (95%CI)** | ***P*** | **OR (95%CI)** | ***P*** |
| +45T/G |  |  |  |  |  |  |  |  |  |
| Total | 10 | 1024 | 1059 | 1.45 (1.26-1.67) | 0.000a | 1.50 (1.25-1.79) | 0.000a | 2.00 (1.42-2.84) | 0.000a |
|  |  |  |  |  |  |  |  |  |  |
| Subgroup |  |  |  |  |  |  |  |  |  |
| Ethnicity |  |  |  |  |  |  |  |  |  |
| Asian | 8 | 945 | 890 | 1.47 (1.27-1.70) | 0.000a | 1.54 (1.27-1.85) | 0.000a | 2.00 (1.43-2.85) | 0.000a |
| SA | 1 | 79 | 169 | 1.21 (0.68-2.41) | 0.510 | 1.13 (0.59-2.15) | 0.710 | 2.18 (0.43-11.07) | 0.350 |
|  |  |  |  |  |  |  |  |  |  |
| +276G/T |  |  |  |  |  |  |  |  |  |
| Total | 5 | 590 | 595 | 0.88 (0.74-1.05) | 0.158 | 0.91 (0.65-1.26) | 0.561 | 0.82 (0.64-1.05) | 0.118 |
|  |  |  |  |  |  |  |  |  |  |
| -11377C/G |  |  |  |  |  |  |  |  |  |
| Total | 5 | 722 | 791 | 0.96 (0.72-1.26) | 0.750 | 1.00 (0.73-1.37) | 0.980 | 0.90 (0.61-1.32) | 0.570 |
|  |  |  |  |  |  |  |  |  |  |
| Subgroup |  |  |  |  |  |  |  |  |  |
| Ethnicity |  |  |  |  |  |  |  |  |  |
| Asian | 2 | 309 | 286 | 1.04 (0.77-1.41) | 0.800 | 1.09 (0.79-1.50) | 0.600 | 0.97 (0.51-1.86) | 0.930 |
| SA | 1 | 79 | 168 | 0.80 (0.50-1.29) | 0.360 | 0.77 (0.44-1.36) | 0.370 | 0.81 (0.28-2.34) | 0.690 |
| European | 2 | 334 | 337 | 0.94 (0.45-1.96) | 0.870 | 1.00 (0.42-2.33) | 0.990 | 0.87 (0.51-1.49) | 0.610 |

a*P* < 0.01. ADIPOQ: Adiponectin; SA: South American; GDM: Gestational diabetes mellitus; SNPs: Single nucleotide polymorphisms; N: Number of study; OR: Odds ratio; CI: Confidence interval; NA: Not assessable.